OncoSec Medical Inc Net debt/EBITDA
¿Qué es el Net debt/EBITDA de OncoSec Medical Inc?
El Net debt/EBITDA de OncoSec Medical Inc es 1.26
¿Cuál es la definición de Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA de compañías en Sector Health Care en NASDAQ en comparadas con OncoSec Medical Inc
¿Qué hace OncoSec Medical Inc?
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar
Empresas con net debt/ebitda similar a OncoSec Medical Inc
- Portmeirion PLC tiene Net debt/EBITDA de 1.26
- Liberty Gold tiene Net debt/EBITDA de 1.26
- Liberty Gold tiene Net debt/EBITDA de 1.26
- Ritter Pharmaceuticals tiene Net debt/EBITDA de 1.26
- Hamilton Lane Inc tiene Net debt/EBITDA de 1.26
- Kalray S.A tiene Net debt/EBITDA de 1.26
- OncoSec Medical Inc tiene Net debt/EBITDA de 1.26
- Reliance tiene Net debt/EBITDA de 1.27
- Greater Bay Area Investments tiene Net debt/EBITDA de 1.27
- Silver Bullet Data Services Gro tiene Net debt/EBITDA de 1.27
- Blende Silver Corp tiene Net debt/EBITDA de 1.27
- Namaste Technologies tiene Net debt/EBITDA de 1.27
- Eros International Plc tiene Net debt/EBITDA de 1.27